Page last updated: 2024-12-11

5-hydroxy-6,8,11,14,17-eicosapentaenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-hydroxy-6,8,11,14,17-eicosapentaenoic acid: RN given refers to (E,Z,Z,Z,Z)-isomer; RN for cpd without isomeric designation not available 4/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-HEPE : A hydroxyicosapentaenoic acid that consists of 6E,8Z,11Z,14Z,17Z-icosapentaenoic acid with the hydroxy group located at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6439678
CHEBI ID72801
SCHEMBL ID5886684
MeSH IDM0163650

Synonyms (30)

Synonym
6,8,11,14,17-eicosapentaenoic acid, 5-hydroxy-, (e,z,z,z,z)-
5-hepe
5-hydroxy-6,8,11,14,17-eicosapentaenoic acid
(+/-)-5-hepe
(+/-)-5-hydroxy-6e,8z,11z,14z,17z-eicosapentaenoic acid
LMFA03070027
NCGC00161247-01
5-hydroxyeicosapentaenoic acid
(+/-)5-hepe
BML1-C02
83952-40-3
(6e,8z,11z,14z,17z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
CHEBI:72801
(+-)-5-hepe
(+-)-5-hydroxy-6e,8z,11z,14z,17z-eicosapentaenoic acid
92008-51-0
SCHEMBL5886684
5-hydroxy-6e,8z,11z,14z,17z-eicosapentaenoic acid
(.+/-.)5-hepe
FTAGQROYQYQRHF-FCWZHQICSA-N
(.+/-.)-5-hydroxy-6e,8z,11z,14z,17z-eicosapentaenoic acid
5(s)-hepe
5-hydroxy-6,8,11,14,17-eicosapentaenoate
(+/-)-5-hydroxy-6e,8z,11z,14z,17z-eicosapentaenoate
5-hydroxyeicosapentaenoate
Q27140155
(+/-)5-hydroxy-6e,8z,11z,14z,17z-eicosapentaenoic acid
DTXSID001258761
(??)5-hepe
AKOS040755364

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" This study evaluated the effect of n-3 PUFA in a low, but recommended cardioprotective dosage on the formation of 5-lipoxygenase pathway metabolites in overweight subjects."( The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: a randomized controlled trial.
Aardestrup, I; Gammelmark, A; Madsen, T; Nielsen, MS; Obel, T; Schmidt, EB, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
HEPEA long-chain polyunsaturated fatty acid that is any icosapentaenoic acid bearing a single hydroxy substituent. An oxidation product of icosapentaenoic acid metabolism.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Biosynthesis of specialized proresolving mediators (SPMs)13107
Biosynthesis of electrophilic -3 PUFA oxo-derivatives227

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's1 (7.14)18.2507
2000's0 (0.00)29.6817
2010's9 (64.29)24.3611
2020's3 (21.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.53 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]